ZAHID HAMID: Open Payments
NPI 1972526978 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,190 in 47 payments from 9 companies in 2025. Trend: 2023 $1,405 · 2024 $1,595 · 2025 $1,190
Food & beverage: $1,190
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $316 |
| Novo Nordisk Inc | 9 | $256 |
| AstraZeneca Pharmaceuticals LP | 10 | $186 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $151 |
| Amgen Inc. | 3 | $78 |
| Exact Sciences Corporation | 3 | $77 |
| Astellas Pharma US Inc | 2 | $49 |
| Dexcom, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $32 |
Products named: CAPLYTA, Ozempic, Kerendia, AIRSUPRA, OTEZLA, Cologuard Collection Kit, Rybelsus, Veozah.
Industry payments across NV — which companies pay providers there.
